Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases

The Anti-Inflammatory Effects of Prostaglandins

(2016) Jose U. Scher et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity

(2011) Vaibhav Kapuria et al.   BIOCHEMICAL PHARMACOLOGY

An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme

(2011) Derek F. Ceccarelli et al.   CELL

Targeting the Ubiquitin E3 Ligase MuRF1 to Inhibit Muscle Atrophy

(2011) Michael J. Eddins et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

The Multifaceted Roles of USP7: New Therapeutic Opportunities

(2011) Benjamin Nicholson et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

DUBs and cancer: The role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors

(2011) Sajjad Hussain et al.   CELL CYCLE

Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib

(2011) Anne C. Mirabella et al.   CHEMISTRY & BIOLOGY

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway

(2011) John S. Schneekloth et al.   CURRENT DRUG TARGETS

Ubiquitin-specific proteases as cancer drug targets

(2011) Wolfgang Sippl et al.   Future Oncology

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

(2011) C. Tom Kouroukis et al.   LEUKEMIA & LYMPHOMA

Constructing and decoding unconventional ubiquitin chains

(2011) Christian Behrends et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Characterization of Selective Ubiquitin and Ubiquitin-Like Protease Inhibitors Using a Fluorescence-Based Multiplex Assay Format

(2010) Xufan Tian et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

The therapeutic potential of deubiquitinating enzyme inhibitors

(2010) Frédéric Colland   BIOCHEMICAL SOCIETY TRANSACTIONS

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

(2010) G. W. Xu et al.   BLOOD

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

(2010) R. T. Swords et al.   BLOOD

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis

(2010) V. Kapuria et al.   CANCER RESEARCH

Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells

(2010) Shinji Endo et al.   CANCER SCIENCE

USP10 Regulates p53 Localization and Stability by Deubiquitinating p53

(2010) Jian Yuan et al.   CELL

Ubiquitin: Same Molecule, Different Degradation Pathways

(2010) Michael J. Clague et al.   CELL

Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress

(2010) Ulrike Seifert et al.   CELL

Synthesis and Biological Evaluation of 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile Analogues as Potential Inhibitors of Deubiquitinating Enzymes

(2010) Matteo Colombo et al.   ChemMedChem

Ubiquitin networks in cancer

(2010) Vladimir Kirkin et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome

(2010) M. Basler et al.   JOURNAL OF IMMUNOLOGY

JBIR-22, An Inhibitor for Protein−Protein Interaction of the Homodimer of Proteasome Assembly Factor 3

(2010) Miho Izumikawa et al.   JOURNAL OF NATURAL PRODUCTS

Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications

(2010) L. V. Pham et al.   MOLECULAR CANCER THERAPEUTICS

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

(2010) James E. Brownell et al.   MOLECULAR CELL

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

(2010) Byung-Hoon Lee et al.   NATURE

An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase

(2010) Stephen Orlicky et al.   NATURE BIOTECHNOLOGY

Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase

(2010) Mariam Aghajan et al.   NATURE BIOTECHNOLOGY

Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A

(2010) Yaron Pereg et al.   NATURE CELL BIOLOGY

Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets

(2010) Lynn Bedford et al.   NATURE REVIEWS DRUG DISCOVERY

Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury

(2010) Hao Liu et al.   NEUROBIOLOGY OF DISEASE

Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1

(2010) L. M. I. Koharudin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Regulation and Cellular Roles of Ubiquitin-Specific Deubiquitinating Enzymes

(2009) Francisca E. Reyes-Turcu et al.   Annual Review of Biochemistry

Therapeutic strategies within the ubiquitin proteasome system

(2009) A G Eldridge et al.   CELL DEATH AND DIFFERENTIATION

Ubiquitination, Ubiquitin-like Modifiers, and Deubiquitination in Viral Infection

(2009) Marisa K. Isaacson et al.   Cell Host & Microbe

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

(2009) M. G. Ooi et al.   CLINICAL CANCER RESEARCH

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

(2009) Y. Tabe et al.   CLINICAL CANCER RESEARCH

Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer

(2009) T. A. Soucy et al.   CLINICAL CANCER RESEARCH

USP7 counteracts SCFβTrCP- but not APCCdh1-mediated proteolysis of Claspin

(2009) Helene Faustrup et al.   JOURNAL OF CELL BIOLOGY

The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection

(2009) M. Basler et al.   JOURNAL OF IMMUNOLOGY

Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction

(2009) John G. Allen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells

(2009) F. Colland et al.   MOLECULAR CANCER THERAPEUTICS

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE

Small-molecule inhibitors of MDM2 as new anticancer therapeutics

(2009) Michael P. Dickens et al.   SEMINARS IN CANCER BIOLOGY

Evaluation of chlorofusin, its seven chromophore diastereomers, and key analogues

(2009) Ryan C. Clark et al.   TETRAHEDRON LETTERS

Ubiquitination system and autoimmunity: The bridge towards the modulation of the immune response

(2008) Diana Gómez-Martín et al.   AUTOIMMUNITY REVIEWS

Role of theVHL(von Hippel–Lindau) gene in renal cancer: a multifunctional tumour suppressor

(2008) Michelle J. Nyhan et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Novel substrates and functions for the ubiquitin-like molecule NEDD8: Figure 1

(2008) Dimitris P. Xirodimas   BIOCHEMICAL SOCIETY TRANSACTIONS

Ubiquitin and ubiquitin-like specific proteases targeted by infectious pathogens: Emerging patterns and molecular principles

(2008) Mariola J. Edelmann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Leucettamol A: A new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis

(2008) Sachiko Tsukamoto et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy

(2008) Q. Chen et al.   BLOOD

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF- B with antimyeloma activity in vitro and in vivo

(2008) R. E. Tiedemann et al.   BLOOD

Itch: a HECT-type E3 ligase regulating immunity, skin and cancer

(2008) G Melino et al.   CELL DEATH AND DIFFERENTIATION

The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network

(2008) Min Sup Song et al.   NATURE

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

(2008) K. Ratia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities

(2008) Benjamin Nicholson et al.   PROTEIN SCIENCE

Recent advances in analytical determination of thalidomide and its metabolites

(2007) M. Espinosa Bosch et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS